We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Increasing awareness about healthcare issues and an aging population are factors that will push the global pharmaceutical market past $900 billion in 2008, according to a new report by a market analysis firm.
Generic firm Par Pharmaceutical and brand drugmaker Advancis Pharmaceutical on June 2 finalized an agreement to develop and co-promote a new branded version of the widely used generic antibiotic amoxicillin.
The global pharmaceutical market will push past $900 billion in 2008, due to an aging population and increasing healthcare awareness worldwide, according to a new report by a market analysis firm.
U.S. states are pulling out all the stops and spending hundreds of millions of dollars in efforts to attract biotechnology firms, according to a new survey of state bioscience initiatives.
Greater transparency about the pricing decisions for biotech and pharmaceutical products could ease growing public and political outrage over the high cost of drugs, according to industry experts at the Biotechnology Industry Organization 2004 convention in San Francisco.
The California Assembly passed bills last week that could, on the one hand, improve drugmakers’ negotiating position with pharmaceutical benefit managers (PBMs) and, on the other hand, add new momentum to the effort to allow importing of prescription drugs from Canada.
The Centers for Medicare & Medicaid Services (CMS) has created a new code for hospitals to use when billing Medicare for approved drugs that have not been assigned billing codes or determined to be eligible for special pass-through payments as new products.
PhRMA has come out swinging in the ongoing battle over drug pricing by rebutting an advocacy group’s recent claims that expected savings under the Medicare discount drug card program will be lost through rapidly increasing prices.